In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2 patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at a median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.
|Original language||English (US)|
|Journal||Clinical infectious diseases : an official publication of the Infectious Diseases Society of America|
|State||Published - Feb 8 2023|
- rebound phenomenon
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases